FDA New Molecular Entity Approvals
This is a record of every genuinely new drug the FDA has approved since 1985. You'll find the drug name, what disease it treats, who made it, and when it got approved. The important part: it marks which drugs got special status. Some got 'priority review' (faster approval), some were for rare diseases (orphan drugs), some got 'breakthrough therapy' status because they looked really promising, and some got approved even faster than normal (accelerated approval). People use this data to answer the big question: do high drug prices actually fund real innovation, or is it just markup? By looking at what kinds of drugs got approved each year and which ones got special designations, you can see if the pipeline is actually producing breakthrough treatments or just minor variations on existing drugs.
- Source rows:
- 1,387
- Coverage:
- 1985-01-01T00:00:00Z – 2025-12-31T00:00:00Z
CSV: all rows from the default table.
Table filters, sorting and pagination are not included.
Explore data
Views organize this dataset for different questions.
Loading views…
Default table
Dataset overview
This overview is independent of the table. Table selections and filters do not change it.
Questions this data answers
- How many new drugs has the FDA approved each year, and what's the trend over time?
- What percentage of approved drugs received breakthrough therapy or accelerated approval designations?
- Which applicants have the most NME approvals since 1985?
- How does the prevalence of orphan drug designations correlate with approval trends?
Download
CSV: all rows from the default table.
Table filters, sorting and pagination are not included.
Columns
27 columns in this table.